My research strives to integrate clinical (e.g., symptoms and signs) and paraclinical measures (e.g., structural/functional/PET neuroimaging, cerebrospinal fluid biomarkers) to inform the pathophysiology of neurodegenerative and autoimmune causes of dementia, while improving diagnostic accuracy, access to disease-modifying therapies, and patient outcomes.